ESOU programme Prostate cancer screening: Why screening programme should not be adopted in > 65 A. Heidenreich, Aachen (DE)

Transcription

1 Friday, 17 January Welcome M. Babjuk, Prague (CZ) M. Brausi, Modena (IT) Opening address ESOU programme Prostate cancer I: Screening, diagnosis, staging and treatment Chairs: M. Brausi, Modena (IT) V. Ravery, Paris (FR) Prostate cancer screening: Why screening programme should not be adopted in > 65 A. Heidenreich, Aachen (DE) Discussion Diagnostic strategies for early detection of PCa A. Govorov, Moscow (RU) Debate: Prostate biopsy and pathological evaluation-how to achieve maximum information Is it time to trash TRUS biopsy? B. Djavan, Vienna (AT) The indication for prostate biopsy in 2014: MRI directed biopsy, is it becoming a standard? A. Villers, Lille (FR) How reliable is the pathological examination to make clinical decisions? R. Montironi, Ancona (IT) The role of tissue biomarkers to predict prognosis Z. Culig, Innsbruck (AT) Discussion Coffee break Active treatment vs active surveillance for low risk PCa in young men Chairs: M. Emberton, London (GB) M. Wirth, Dresden (DE) Robotic RP (video) B. Rocco, Milan (IT) Focal therapy M. Emberton, London (GB) Active surveillance L. Klotz, Toronto (CA) Discussion

2 Friday, 17 January - continued Renal Cancer: Localised Chairs: P. Mulders, Nijmegen (NL) H. Özen, Ankara (TR) Can we predict histology of renal tumors by imaging and macroscopic appearance? Clinical consequences M. Hora, Pilsen (CZ) New pathological classification: Grading F. Algaba, Barcelona (ES) Debate: The best treatment for renal masses > 3 cm in the elderly (>75) patients Active surveillance: Has it a role? A. Volpe, Novara (IT) Ablation therapy: Pro R. Illing, London (GB) Surgery: Still the best? G. Janetscheck, Salzburg (AT) Discussion Lunch Penile cancer Chairs: F. Algaba, Barcelona (ES) A. Govorov, Moscow (RU) Pre-Malignant lesions: Incidence and classifications F. Algaba, Barcelona (ES) Mini-invasive therapies for clinically localised penile tumours C. Protzel, Rostock (DE) Urothelial cancer I: Non muscle invasive Chairs: V. Altieri, Salerno (IT) J. Palou, Barcelona (ES) Circulating tumor cells in bladder cancer: A new marker? A. Alcaraz, Barcelona (ES) Debate: Standard TUR and cytology vs TUR and new technologies Standard TUR: T. O Brien, London (GB) New technologies: F. Witjes, Nijmegen (NL) Coffee break Bladder Cancer Prevention Program: An international initiative by Maurizio Brausi M. Brausi, Modena (IT) Urothelial cancer II: Non muscle invasive Chairs: V. Altieri, Salerno (IT) J. Palou, Barcelona (ES)

3 Friday, 17 January - continued Debate: Treatment of intermediate risk patients: Chemotherapy vs BCG Chemo is appropriate: P-U. Malmström, Uppsala (SE) BCG is the best: L. Martinez Pineiro, Madrid (ES) Discussion BCG in the elderly: Still a good choice? M. Colombel, Lyon (FR) Discussion Best NMIBC papers G. Giannarini, Berne (CH)

4 Saturday, 18 January Prostate cancer II: Localised Chairs: B. Djavan, Vienna (AT) G. Janetschek, Salzburg (AT) Treatment algorithm in high risk Pca P-A. Abrahamsson, Malmö (SE) Debate: High risk clinically localised Pca Radical prostatectomy: How I do it step by step (Video) H. Van Poppel, Leuven (BE) Radiotherapy is better: New technologies (Cyberknife, Protons..) A. Bossi, Villejuif (FR) Robotic radical prostatectomy and extended lymphadenectomy for ct3 Pca: Surgical technique and outcomes (Video and lecture) P. Wiklund, Stockholm (SE) Laparoscopic RP for ct3: Same results but less expensive? J. Rassweiler, Heilbronn (DE) Discussion Testicular cancer Chairs: P. Albers, Düsseldorf (DE) B. Rocco, Milan (IT) Standard treatment and new messages in the management of Stage I disease T. Tandsted, Trondheim (N) New messages in intermediate and poor risk disease A. Horwich, Sutton (GB) Surgical approaches in complex cases V. Matveev, Moscow (RU) Discussion Coffee break Urothelial cancer III: Muscle invasive and advanced disease Chairs: W. Artibani, Verona (IT) G.N. Thalmann, Berne (CH) Radical cystectomy and orthotopic neobladder in women: Long term results and QoL A. Stenzl, Tübingen (DE) Debate: Prostate sparing radical cystectomy Defending: M. Brausi, Modena (IT) Challenging: M. Babjuk, Prague (CZ) Discussion

5 Saturday, 18 January - continued Debate: Therapeutic strategies in elderly (>75) and frail patients with muscle-invasive bladder cancer Geriatric evaluation (definition of frail and clinical impact) F. Montorsi, Milan (IT) Surgery P. Albers, Düsseldorf (DE) Radio-chemotherapy H. Van Der Poel, Amsterdam (NL) Local control and best supportive care L. Türkeri, Istanbul (TR) Discussion STEPS (Session To Evaluate Progress) programme (closed programme: participation by invitation only) Led by Prof. M. Brausi, Modena (IT) Prostate Cancer table Chair: L. Klotz, Toronto (CA) Bladder Cancer table Chair: A. Stenzl, Tübingen (DE) Kidney Cancer table Chair: P. Mulders, Nijmegen (NL)

6 Sunday, 19 January Disaster management and prevention in uro-oncological surgery (open, robotic and lap) Chairs: T. Hanus, Prague (CZ) H. Van Poppel, Leuven (BE) Intra-OP V. Pansadoro, Rome (IT) Late V. Pansadoro, Rome (IT) Case Discussion Case presenter: M. Babjuk, Prague (CZ) Panel: A. Stenzl, Tübingen (DE) W. Artibani, Verona (IT) V. Pansadoro, Rome (IT) P-A. Abrahamson, Malmö (SE) Cytoreductive surgery in metastatic disease Chair: G. Mickisch, Bremen (DE) F. Montorsi, Milan (IT) Rationale J. Catto, Sheffield (GB) Kidney H. Van Poppel, Leuven (BE) Bladder J. Palou, Barcelona (ES) Prostate A. Heidenreich, Aachen (DE) Discussion Coffee break Muscle invasive Bladder Cancer Chairs: S. Brewster, Oxford (GB) L. Jarolim, Prague (CZ) Standardising complications reporting after radical cystectomy G. Thalmann, Berne (CH) Functional outcomes of orthotopic reservoirs following radical cystectomy. Searching the truth W. Artibani, Verona (IT) Discussion

7 Sunday, 19 January - continued Prostate Cancer III: Advanced and metastatic Chair : A. Heidenreich, Aachen (DE) P. Albers, Düsseldorf (DE) Intermittent vs continuous ADT: Still controversial? P.A. Abrahamsson, Malmö (SE) Local treatment of oligometastatic disease: Lymphadenectomy A. Briganti, Milan (IT) Bone metastases S. Joniau, Leuven (BE) When should we start treatment in CRPC patients? P. Albers, Düsseldorf (DE) Discussion End of the ESOU meeting M. Babjuk, Prague (CZ) M. Brausi, Modena (IT)